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An earlier review summarized evidence relating use of snus (Swedish-type moist snuff) to health and to initiation
and cessation of smoking. This update considers the effect recent publications on snus use and health have on the
overall evidence. The additional evidence extends the list of neoplastic conditions unassociated with snus use
(oropharynx, oesophagus, stomach, lung) to include colorectal cancer and acoustic neuroma, and further
undermines the weakly-based argument that snus use increases the risk of pancreatic cancer, although there is a
report of poorer cancer survival in users. It remains undemonstrated that “snuff-dipper’s lesion” increases risk of oral
cancer, and recent publications add to the evidence that snus use has no effect on periodontitis or dental caries.
Although onset of acute myocardial infarction is not adversely associated with snus use, there is some evidence of
an association with reduced survival. Whether this is a direct effect of snus use or a result of confounding by socio-
economic status or other factors requires further investigation, as does a report of an increased risk of heart failure
in snus users. Even if some adverse health effects of snus use do exist, it remains clear that they are far less than
those of smoking.
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Background
Swedish-type moist snuff (“snus”) consists of finely
ground air- or sun-cured tobacco, salt (sodium chloride),
water, humidifying agents, chemical buffering agents
(sodium carbonate), and food-grade flavourings. It is
manufactured using a heat treatment process and, be-
cause of the manufacturing methods and selection of
snus tobaccos, has stable levels of certain unwanted con-
stituents, such as tobacco-specific nitrosamines, which
are low compared to smokeless products prevalent on
the US market, such as US-style moist snuff [1,2]. A
pinch (or dip) of snus is placed between the gum and
upper lip, often for 11 to 14 hours daily [3], in contrast
to US finely cut moist snuff (or chewing tobacco) which
is held (or chewed) in the gingival buccal area [4]. Use of
snus involves nicotine exposure similar to and perhaps
somewhat greater than that from smoking [5-11].Correspondence: PeterLee@pnlee.co.uk
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In recent years there has been considerable interest in
snus as a possible safer alternative to smoking. However,
attention has been drawn to possible health effects of
snus use. A review in 2008 for the EC [12] referred to its
carcinogenicity, citing the pancreas as a major target
organ, to the localized oral lesions it causes, and to pos-
sible risks of oral cancer and acute myocardial infarction
(AMI). Following a series of reviews of the effects of
smokeless tobacco on the various specific diseases of
interest in which I was involved [4,13-16] I published, in
2011, a comprehensive review, including meta-analysis,
of the epidemiological evidence relating snus to health
[17]. My review concluded that “the evidence provides
scant support for any major adverse health effects of
snus”. Among my detailed conclusions I noted that the
overall data showed no association of snus with heart dis-
ease or stroke or with various types of cancer (oropharynx,
oesophagus, stomach, lung) and that the characteristicis an open access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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For pancreatic cancer, the evidence, as discussed more
fully elsewhere [15] is limited and difficult to interpret,
but overall does not show a statistically significant in-
creased risk, either for never smokers, or for the whole
population (with adjustment for smoking).
Since my comprehensive review [17] appeared I be-
came aware of two more recent publications providing
major new findings, one on pancreatic cancer [19], the
other on AMI [20], diseases which are particularly rele-
vant to the debate concerning the safety or otherwise of
snus. It was therefore felt important to update my re-
view, taking into account not only these two papers, but
also other recent publications on snus use and health, in
order to determine the effect they had on the overall
conclusions. The update is limited to neoplastic condi-
tions, circulatory disease (CID) and oral conditions.
Methods
Methods are as previously described [17], with searches
updated to 18th November 2012. Results are only sum-
marized for health effects where new relevant publica-
tions could be identified.
Results
Nine new relevant publications were identified [19-27].
Pancreatic cancer
An earlier review of smokeless tobacco and risk of pan-
creatic cancer [15] considered nine North American and
two Scandinavian studies. Seven of these provided esti-
mates of the relative risk (RR) associated with smokeless
tobacco use, based on data for smokers and nonsmokers
combined, and with adjustment for smoking (the “smok-
ing-adjusted relative risk”) and five provided estimates
based on data for never smokers. Meta-analysis gave a
combined estimate of the smoking-adjusted RR of 1.07
(95% confidence interval [CI] 0.71-1.60), and of 1.23
(95% CI 0.67-2.31) for the risk in never smokers. While
there was little evidence of an increase in the North
American studies, the two Scandinavian studies showed
rather more indication of an increase. One [28] reported
a significant increase (2.00, 95% CI 1.20-3.30) in never
smokers, but not (0.90, 95% CI 0.70-1.20) in the
smoking-adjusted analysis. The other [29], conducted in
Norway, reported no increase (0.85, 95% CI 0.24-3.07) in
never smokers, but did report a significant increase
(1.67, 95% CI 1.12-1.50) in the smoking-adjusted ana-
lysis. This study has been criticized [30-33] for various
reasons, including failure to adjust for alcohol, using an
exposed group which included a completely different
type of smokeless tobacco (skrá) as well as snus, and a
very long follow-up with no updating of tobacco use.
The EC report [12] misleadingly reported only thesignificant associations, leading to their conclusion that
the pancreas was a main “target organ”, ignoring the fact
that the combined evidence from those two studies did
not show a significant increase, either for never smokers
(1.61, 95% CI 0.77-3.34) or based on the smoking-
adjusted RRs (1.20, 95% CI 0.66-2.20).
While there are no new studies on pancreatic cancer
and snus, attention should be drawn to a recent paper
[19] reporting the results of a pooled analysis relating
pancreatic cancer to the use of forms of smokeless to-
bacco other than snus, based on 11 case-control studies,
none in Scandinavia. Compared to never users of to-
bacco, the odds ratio (OR) was estimated as 0.98 (95%
CI 0.75-1.27) for ever smokeless tobacco users and 0.62
(95% CI 0.37-1.04) for smokeless tobacco only users.
Although it has been argued [34] that the case-control
studies are subject to bias for various reasons, and that
the two cohort studies [29,35] are “strong”, it would
nevertheless seem that these results strengthen the argu-
ment that snus use is unassociated with an increased
pancreatic cancer risk, especially since nitrosamine levels
are substantially lower in snus than in other types of
smokeless tobacco [36], nitrosamines being considered
“the major and most abundant group of carcinogens” in
smokeless tobacco products [12].
One must conclude that the evidence for an associ-
ation of snus with pancreatic cancer, already weakly
based before the pooled analysis [19], has become even
more weakly based.
Oral cancer
The direct epidemiological evidence previously consid-
ered [17] found no increased risk of oropharyngeal can-
cer associated with snus use, either in never smokers
(RR 1.01, 95% CI 0.71-1.45, n = 4) or based on smoking-
adjusted results (RR 0.97, 95% CI 0.68-1.37, n = 7), a
result supported by long-term follow-up of 1115 individ-
uals with snuff-dippers lesion, which observed no can-
cers at the site of lesions seen initially [37]. It is also
consistent with evidence of a lack of increased risk asso-
ciated with smokeless tobacco use in US populations in
studies published since 1990 [4,16].
A recent paper [21] described 16 male patients with
oral squamous cell carcinoma seen in seven Swedish
hospitals, with the cancers reported to have occurred at
the “exact anatomical location” where snus had been
used for several years. The authors concluded that
“Swedish snuff may not be a harmless alternative to
smoking”. The difficulty in interpreting these results is
that there is no control information on the distribution
of sites among other oral cancer patients who used snus,
or among patients who did not use snus, so that one
cannot judge whether oral cancer is more likely than ex-
pected to be seen at the site of use. Even if snus does
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demiological evidence strongly suggests that any in-
creased risk is small, and substantially less than that
associated with smoking.
Colorectal cancer
A recent study [22] is the first to report results relating
to a possible association of snus with colon or rectal
cancer. The study involved follow-up to 2007 of 336,381
male Swedish construction workers for whom detailed
information on tobacco use at cohort entry had been
collected in 1971-1992. Age- and BMI- adjusted RRs
comparing pure snus users and non-users of any tobacco
were presented by duration of use, but no evidence of an
association was seen for cancers of the colon (based on
n = 153 cases in users), or the rectum (n = 97), separate
results being also presented for the right- and left-sided
colon (n = 59 and 60 respectively). Anal cancers were
also studied, but only one case was seen in users. Some
limitations of the Construction Workers Study, which
has reported results for many health endpoints, are dis-
cussed elsewhere [17].
Acoustic neuroma
At the time of my earlier review [17], there was no evi-
dence relating snus use to acoustic neuroma. A recent
paper [24] described a study in Sweden conducted in
2002 to 2007, involving 451 cases and 710 population-
based controls. Risk of acoustic neuroma, adjusted for
education and tobacco use, was unassociated with
current snus use (OR 0.94, 95% CI 0.57-1.55) or former
snus use (OR 1.22, 95% CI 0.71-2.10). This contrasted
with a marked reduction in risk associated with current
smoking (OR 0.41, 95% CI 0.23-0.74), prompting the
authors to suggest that protection may be conferred by a
constituent of tobacco smoke other than nicotine.
Survival from cancer
A recent paper [23] concerns survival from cancer
among 40,320 male Swedish construction workers,
24,826 of whom had died. Compared to never tobacco
users, an increased risk of death was evident in all to-
bacco groups studied after adjustment for age at diagno-
sis, period of diagnosis, cancer site and BMI, whether
the death was from the primary cancer or another cause.
The RR of overall mortality was 1.13 (95% CI 1.05-1.20)
for pure snus users, 1.21 (1.17-1.25) for pure smokers
and 1.17 (1.12-1.22) for combined users. For cause-
specific mortality RRs for pure snus users (1.15, 1.05-
1.26) and pure smokers (1.15, 1.10-1.21) were similar.
The authors comment on their inability to control for
stage of cancer at diagnosis, though did show that the
increased mortality in pure snus users was similar in
those with or without comorbidity. The authors notedthat the mechanism behind the poorer survival in pure
snus users warranted further investigation, and sug-
gested that “nicotine may play a role”.
Circulatory disease
Table four of my earlier review [17] summarized results
relating snus use to ischaemic heart disease (IHD), AMI,
stroke and any CID separately for never smokers and for
the whole population with adjustment for smoking.
None of the meta-analysis RR estimates were significant
(p < 0.05) or exceeded 1.10 and I concluded that
“although a small effect of snus on the incidence of CID
cannot be excluded, this has not been demonstrated by
the available epidemiological data”.
A recent paper [20] describes the results of a pooled
analysis from eight prospective observational studies of
the relationship of snus use to AMI, based on men who
never smoked. Table 1 summarizes the total evidence re-
lating snus use in male never smokers incorporating this
latest data, and excluding those results reported earlier
[38-40] which are superseded by the later individual
study results given for the pooled analysis. Based on the
13 individual estimates of RR/OR the combined fixed
effect estimate is 1.07 (95% CI 0.98-1.16). However, there
is significant (p = 0.06) heterogeneity, and the random-
effects estimate is 1.06 (95% CI 0.91-1.23). The major
contributor to the heterogeneity is the individual esti-
mate of 1.35 (95% CI 1.13-1.62) from the analysis of the
Construction Workers Study based on interviews in
1971-1974. The heterogeneity may well have arisen be-
cause the results for this study relate to a period when
the form of snus used was different. Also, during 1971-
74, the data collected by questionnaire were limited for
snus use and ambiguously coded for smoking [17]. Fur-
thermore, it is the only estimate based only on fatal
cases. Restricting attention to the other 12 estimates, the
combined fixed effect estimate becomes 1.00 (95% CI
0.91-1.10) with no statistical evidence of heterogeneity.
While these results seem consistent with a lack of
effect of snus use on AMI, it should be noted that the
pooled analysis [20], though reporting no association of
snus use with the combined incidence of fatal and non-
fatal AMI (RR 1.04, 95% CI 0.93-1.17) and no significant
association with level or duration of use, did report that
the short-term fatality rate “appeared increased” in snus
users (OR 1.28, 95% CI 0.99-1.68). However the authors
noted that this relationship “may be due to confounding
by socioeconomic or life style factors”, and that con-
founding by level of education could not be addressed in
this analysis due to lack of relevant data.
Results relating to the short-term fatality rate were not
presented by study, but it seems clear that they largely
depended on the findings from the Construction
Workers Study which contributed 88% of the total
Table 1 RR/OR of IHD/AMI for current (vs. never) snus use in never smoking Swedish men
Source Study Typea Periodb Casesc End-pointd RR/OR (95% CI) Adjustment factorse
Bolinder et al. [41] Construction Workers PC 1971-74/1985 172 F 1.35 (1.13-1.62)f age, res
Haglund et al. [42] Survey of living conditions PC 1988-89/2003 28 F + NF 0.77 (0.51-1.15)g,h age, exe, hea, ill, res, ses
Wennberg et al. [43] VIPi and MONICAj NCC 1985-99/1999 21 F + NF 0.82 (0.46-1.43) age, bmi, cho, edu, lei, phy
Huhtasaari et al. [44] 1st MONICAj study CC 1989-91 59 F + NF 0.89 (0.62-1.29)g,h age
Huhtasaari et al. [45] 2nd MONICAj study CC 1991-93 59 F + NF 0.93 (0.65-1.34)f,h none
Hergens et al. [46] Two counties CC 1992-94 10 F + NF 0.73 (0.35-1.50) age, res
Hansson et al. [20] Construction Workersk PC 1978-93/20y 309 F + NF 1.01 (0.90-1.14) age
Malmö diet and cancerl PC 1991-96/13y 4 F + NF 1.00 (0.37-2.70) age
MONICA N.Sweden PC 1986-2004/11y 7 F + NF 0.77 (0.35-1.69) age
National March Cohort PC 1997/9y 0 F + NF - age
SALTm PC 1998-2002/8y 21 F + NF 1.56 (0.98-2.48) age
Stockholm Public Health PC 2002/5y 5 F + NF 1.21 (0.48-3.08) age
Scania Public Health PC 1991-2000/8y 8 F + NF 1.90 (0.90-4.00) age
WOLFn PC 1992-98/9y 2 F + NF 3.30 (0.63-17.1) age
Total 13 estimates Fixedo 1.07 (0.98-1.16) Het p = 0.06
Randomp 1.06 (0.91-1.23)
Excluding [41] 12 estimates Fixedo 1.00 (0.91-1.10) Het p = 0.34
Randomp 1.00 (0.88-1.13)
aPC = prospective cohort, NCC = nested case-control, CC = case-control.
bFor case-control studies, the period of interviewing is shown. For prospective cohort or nested case-control studies, the baseline period is shown before the /,
and either the final year of follow-up or, where this is not available, the mean person-years of follow-up after the /.
cThe number of cases exposed to snus.
dF = fatal, NF = non-fatal.
eAbbreviations used: bmi body mass index, cho cholesterol level, edu education, exe exercise, hea self reported health, ill longstanding illness, lei leisure time,
phy physical activity, res area of residence, ses socioeconomic status.
fEstimated from data in source article.
gEstimate is for current v non-current snus users.
hEstimate is for non-current smokers.
iVIP = Vasterbötten Intervention Program.
j MONICA =Multinational Monitoring of trends and determinants in Cardiovascular disease.
kResults supersede those reported earlier [38].
lResults supersede those reported earlier [39].
mSALT = Screening across the lifespan twin study, results supersede those reported earlier [40].
nWOLF =Work, lipids and fibrinogen.
o“Fixed” – the result of the fixed effect meta-analysis is shown on the right followed by the between-study heterogeneity p value (“Het p”).
p“Random” – the result of the random-effects meta-analysis is shown on the right.
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with an earlier report from this study [38] which re-
ported a significantly increased risk in never smokers as-
sociated with current snus use for fatal cases (RR 1.32,
95% CI 1.08-1.61) but a non-significantly decreased risk
for non-fatal cases (RR 0.70, 95% CI 0.48-1.02). It should
be noted that there are four other studies [42,43,45,46]
which have separately reported results for fatal cases and
either non-fatal cases or all cases combined. While (see
Table 2) the estimates for fatal cases from those studies
all have wide variability, it is interesting to note that in
all these studies risks are also above 1.0 for fatal cases
and below 1.0 for non-fatal cases. The combined RR/OR
estimated from the five studies is 1.31 (95% CI 1.09-
1.58) for fatal cases and 0.89 (95% CI 0.79-1.00) for non-
fatal cases, with no evidence of heterogeneity. Taken at
face-value, these results suggest that current snus use innever smokers may be associated with a slightly reduced
risk of non-fatal AMI/IHD, but with an increased risk of
fatal cases. Whether the increased risk of fatal cases re-
flects a direct effect of snus or an effect of confounding
(e.g. a tendency for snus users to report disease later or
have less medical care when they do) requires further
investigation. In any case, it is evident that any true in-
crease in risk of AMI resulting from snus use, if it exists,
is very much less than that from smoking.
Another recent relevant publication [25] investigated
the relationship between snus and risk of heart failure
based on results from two Swedish cohorts. One was the
Construction Workers Study, where an analysis in never
smokers including 75 cases in current snus users
reported a marginally significant RR of 1.28 (95% CI
1.00-1.64) after adjustment for age, BMI, region and
AMI before baseline. However, no dose-response was
Table 2 RR/OR of IHD/AMI for current (vs. never) snus use – by case fatalitya
Source Fatal Non-fatalb Ratio fatal to non-fatalc
Haglund et al. ([42])d 1.15 (0.54-2.41) 0.65 (0.40-1.06) 1.77 (0.72-4.31)
Wennberg et al. ([43])e 1.12 (0.38-3.29) 0.73 (0.37-1.42) 1.54 (0.43-5.42)
Huhtasaari et al. ([45])f 1.50 (0.45-5.03) 0.36 (0.15-0.85) 4.22 (0.96-18.64)
Hergens et al. ([46]) 1.70 (0.48-5.50) 0.59 (0.25-1.40) 2.88 (0.65-12.82)
Hergens et al. ([38]) 1.32 (1.08-1.61) 0.94 (0.83-1.06) 1.40 (1.11-1.77)
Totalg 1.31 (1.09-1.58) 0.89 (0.79-1.00) 1.48 (1.19-1.84)
aRR/ORs are based on data for male never smokers. Adjustment factors are as in Table 1 except where stated.
bFor the first three studies, RR (CI) for non-fatal cases have been estimated from those for fatal cases and for combined fatal and non-fatal cases.
cRR (CI) for the ratio estimated from those for fatal and non-fatal cases.
dEstimates are for current v non-current snus use, based on non-current smokers.
eFatal cases are fatal within 28 days of onset.
fWhereas the results in Table 1 for this study are unadjusted results for non-current smokers comparing current and never snus users, the results in Table 2 are
results for non-current smokers comparing ever and never regular snus users with adjustment for hypertension, education, marital status, diabetes, cholesterol
and family history of AMI.
gFixed-effects estimates. There was no evidence of heterogeneity; with p = 0.98 for fatal, p = 0.10 for non-fatal and p = 0.55 for the ratio.
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the Uppsala Longitudinal Study. Here, the analysis in-
cluded smokers and nonsmokers, and included 14 heart
failure cases in snus users, the association again being
marginally significant (RR 2.08, 95% CI 1.03-4.22). As
the authors pointed out, the findings “need confirmation
in further studies and underlying mechanisms remain to
be elucidated”.Periodontitis and dental caries
The earlier review [17] briefly summarized evidence re-
lated to various aspects of non-neoplastic oral disease.
Though there were some reports of increased risks of
gingival disease [47] or of dental caries [48], more stud-
ies showed no effects on such diseases [49-52] and it
was evident that any association of snus use with peri-
odontal and gingival disease or with dental caries was
not established.
These conclusions are supported by two recent publi-
cations [26,27] based on stratified random samples of
the population of Jönköping, Sweden aged 20, 30, 40, 50,
60 and 70 years, taken in 1983, 1993 and 2003. After
adjusting for age, sex and sociodemographic variables
snus users were found to have no increased risk of peri-
odontitis [26] or of dental caries [27].Discussion
Based on my previous review [17], I concluded that snus
use is clearly much safer than smoking, and that any
effects of snus use on the risk of cancer or CID, if they
exist, are probably no more than 1% of that of smoking.
I also noted that switching to using snus should improve
the health prospects of those smokers unable or unwill-
ing to relinquish nicotine, and that there is no good
evidence that introducing snus into a population would
encourage smoking initiation or discourage cessation.While this update does not consider evidence relating
snus use to initiation or cessation of smoking, it does
provide further information on possible health effects as-
sociated with snus use. As regards neoplastic conditions,
recent evidence extends the list of those unassociated
with snus use to include colorectal cancer [22] and
acoustic neuroma [24], and, for pancreatic cancer [19]
adds further weight to undermine the claims [12,53] of
an adverse effect of snus use, claims that have already
been shown to be unsoundly based [15-17]. The recent
publication [21], which reports some cases of oral can-
cers occurring at the site where snus has been placed,
does not provide evidence of effect in the absence of
control data on the distribution of sites of oral cancer
among all snus users and among non-users. Here, the
epidemiological evidence suggests that if there is an
increased risk it is small, and much less than that associ-
ated with smoking. Despite the lack of evidence that
snus use increases risk of cancer, the recent observation
[23] that it is associated with poorer survival demands
further investigation.
New publications on periodontitis [26] or dental caries
[27] also add to the evidence that snus use has no effect
on non-neoplastic oral lesions, other than causing
“snuff-dippers lesion” [18], which has not been shown to
be predictive of cancer.
Although the evidence remains clear that effects of snus
use on risk of CID, if they exist, are much less than those
of smoking, recent publications have provided evidence of
increased risk in snus users of heart failure [25] and of case
fatality from AMI [20]. More evidence on both these issues
is needed. For AMI, this review presents evidence from five
studies [38,42,43,45,46] that snus use, in never smokers, is
associated with a somewhat reduced risk of non-fatal AMI,
but with an increased risk of fatal AMI. The extent to
which this difference reflects true effects of snus or uncon-
trolled confounding requires further investigation.
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Adverse health effects of snus use have not been clearly
identified. The recent literature strengthens the evidence
that any cancer risk (including that of pancreatic cancer)
is at most minimal, and certainly much less than that
associated with smoking. However, it does suggest that
snus use might adversely affect survival from cancer. Al-
though there is little evidence that snus use is associated
with onset of AMI or stroke, reports of an increased risk
of fatal AMI require further investigation.
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